Contact
searchSearch
HMP Global
Login

Multiple Myeloma Excellence Forum

Multiple Myeloma
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Joshua Richter, MD
Conference Coverage
Benefits of Dual Maintenance Therapy for Treating Multiple Myeloma Following Transplantation
08/20/2025
Joshua Richter, MD
At the 2025 Great Debates in Hematologic Malignancies meeting, Joshua Richter, MD, argues for the benefits of dual maintenance therapy following autologous stem cell transplantation to improve responses among patients with multiple myeloma.
At the 2025 Great Debates in Hematologic Malignancies meeting, Joshua Richter, MD, argues for the benefits of dual maintenance therapy following autologous stem cell transplantation to improve responses among patients with multiple myeloma.
At the 2025 Great Debates in...
08/20/2025
Oncology
Noa Biran, MD
Conference Coverage
Evaluating the Role of Dual Maintenance Therapy for Patients With MM Following Transplant
08/20/2025
Noa Biran, MD
Noa Biran, MD participated in a debate on the role of dual maintenance therapy following transplant for patients with multiple myeloma at the 2025 Great Debates in Hematologic Malignancies meeting.
Noa Biran, MD participated in a debate on the role of dual maintenance therapy following transplant for patients with multiple myeloma at the 2025 Great Debates in Hematologic Malignancies meeting.
Noa Biran, MD participated in a...
08/20/2025
Oncology
FDA Approval
FDA Approves Linvoseltamab-gcpt for Patients With Relapsed/Refractory Multiple Myeloma
07/02/2025
Emily Estrada
The US FDA approved linvoseltamab-gcpt for the treatment of adults with relapsed/refractory multiple myeloma based on results from the LINKER-MM1 clinical trial.
The US FDA approved linvoseltamab-gcpt for the treatment of adults with relapsed/refractory multiple myeloma based on results from the LINKER-MM1 clinical trial.
The US FDA approved...
07/02/2025
Oncology
Amrita Krishnan, MD, FACP
Conference Coverage
Evaluating the Evolving Role of Stem Cell Transplantation for Patients With Multiple Myeloma
06/30/2025
Amrita Y. Krishnan, MD, FACP
Amrita Krishnan, MD, FACP, participated in a debate covering new data on the use of stem cell transplantation for patients with multiple myeloma at the 2025 Great Debates in Hematologic Malignancies meeting.
Amrita Krishnan, MD, FACP, participated in a debate covering new data on the use of stem cell transplantation for patients with multiple myeloma at the 2025 Great Debates in Hematologic Malignancies meeting.
Amrita Krishnan, MD, FACP,...
06/30/2025
Oncology
Tarun Wasil, MD
Conference Coverage
Evaluating Potential Treatment Strategies for Patients With Multiple Myeloma
06/28/2025
Tarun Wasil, MD
Tarun Wasil, MD, discusses treatment initiation and discontinuation for patients with multiple myeloma in various stages at the 2025 Great Debates in Hematologic Malignancies meeting.
Tarun Wasil, MD, discusses treatment initiation and discontinuation for patients with multiple myeloma in various stages at the 2025 Great Debates in Hematologic Malignancies meeting.
Tarun Wasil, MD, discusses...
06/28/2025
Oncology
Rajshekhar Chakraborty, MD
Conference Coverage
Linvoseltamab Plus Carfilzomib Achieves Deep, Durable Responses for Triple-Class Exposed Multiple Myeloma
06/11/2025
Rajshekhar Chakraborty, MD
Rajshekhar Chakraborty, MD shares results from the LINKER-MM2 trial which assessed the safety and efficacy of linvoseltamab plus carfilzomib for patients with heavily pretreated relapsed/refractory multiple myeloma.
Rajshekhar Chakraborty, MD shares results from the LINKER-MM2 trial which assessed the safety and efficacy of linvoseltamab plus carfilzomib for patients with heavily pretreated relapsed/refractory multiple myeloma.
Rajshekhar Chakraborty, MD...
06/11/2025
Oncology
Syed Maaz Tariq, MD
Conference Coverage
Non-BCMA CAR T-Cell Therapy Shows Promise for the Treatment of Relapsed/Refractory Multiple Myeloma
06/04/2025
Syed Maaz Tariq, MD
Syed Maaz Tariq, MD, shares results from a retrospective analysis showing non-BCMA CAR T-Cell therapies, such as GPRC5D, demonstrate efficacy and safety for patients with relapsed/refractory multiple myeloma.
Syed Maaz Tariq, MD, shares results from a retrospective analysis showing non-BCMA CAR T-Cell therapies, such as GPRC5D, demonstrate efficacy and safety for patients with relapsed/refractory multiple myeloma.
Syed Maaz Tariq, MD, shares...
06/04/2025
Oncology
Peter Voorhees, MD
Conference Coverage
CARTITUDE-1: Ciltacabtagene Autoleucel Demonstrates Durable Long-Term Remission in R/R MM
06/03/2025
Peter Voorhees, MD
Peter Voorhees, MD, discusses long-term results from the CARTITDE-1 trial, which demonstrated durable and deep responses at 5 years following ciltacabtagene autoleucel infusion among patients with heavily pretreated relapsed/refractory MM.
Peter Voorhees, MD, discusses long-term results from the CARTITDE-1 trial, which demonstrated durable and deep responses at 5 years following ciltacabtagene autoleucel infusion among patients with heavily pretreated relapsed/refractory MM.
Peter Voorhees, MD, discusses...
06/03/2025
Oncology
C. Ola Landgren, MD, PhD
Videos
Updates in Frontline Therapies for Patients With Transplant-Ineligible Multiple Myeloma
03/21/2025
C. Ola Landgren, MD, PhD shares updates on improvements in cancer outcomes, including prolonged survival and tolerability, for patients with newly diagnosed multiple myeloma who are transplant-ineligible.
C. Ola Landgren, MD, PhD shares updates on improvements in cancer outcomes, including prolonged survival and tolerability, for patients with newly diagnosed multiple myeloma who are transplant-ineligible.
C. Ola Landgren, MD, PhD shares...
03/21/2025
Oncology
Victor Jimenez-Zepeda, MD
Videos
Advancements in Treating Patients with Precursor Disorders of Multiple Myeloma
02/24/2025
Victor Jimenez-Zepeda, MD, discusses updates in clinical trials for treatment of smoldering multiple myeloma and monoclonal gammopathy of undetermined significance prior to development of symptomatic multiple myeloma.
Victor Jimenez-Zepeda, MD, discusses updates in clinical trials for treatment of smoldering multiple myeloma and monoclonal gammopathy of undetermined significance prior to development of symptomatic multiple myeloma.
Victor Jimenez-Zepeda, MD,...
02/24/2025
Oncology

Section Editor

Shaji Kumar, MD
Mayo Clinic, Rochester, Minnesota

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use